ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs MXN
20.7185
0.00%
Brent Oil
79.285
0.00%
Bitcoin
94,322.25
-0.26%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cogent Biosciences Inc (COGT)

  7. Cogent Biosciences Inc (COGT) Noticias

COGT

Cogent Biosciences (COGT)

Cogent Biosciences Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:COGT
FechaHoraFuenteTítuloSímboloCompañía
08/01/202507:00GlobeNewswire Inc.Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:COGTCogent Biosciences Inc
09/12/202415:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
09/12/202406:00GlobeNewswire Inc.Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsNASDAQ:COGTCogent Biosciences Inc
08/12/202411:00GlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)NASDAQ:COGTCogent Biosciences Inc
14/11/202415:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:COGTCogent Biosciences Inc
12/11/202407:00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
05/11/202408:00GlobeNewswire Inc.Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) MeetingNASDAQ:COGTCogent Biosciences Inc
23/10/202406:00GlobeNewswire Inc.Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:COGTCogent Biosciences Inc
03/09/202407:00GlobeNewswire Inc.Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility AnalysisNASDAQ:COGTCogent Biosciences Inc
06/08/202415:53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:COGTCogent Biosciences Inc
06/08/202407:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
06/08/202407:00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
27/06/202407:00GlobeNewswire Inc.Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trialNASDAQ:COGTCogent Biosciences Inc
14/06/202406:30GlobeNewswire Inc.Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)NASDAQ:COGTCogent Biosciences Inc
13/06/202418:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
13/06/202405:06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
29/05/202415:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
23/05/202416:05GlobeNewswire Inc.Cogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerNASDAQ:COGTCogent Biosciences Inc
23/05/202416:01GlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual MeetingNASDAQ:COGTCogent Biosciences Inc
07/05/202407:00GlobeNewswire Inc.Cogent Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
09/04/202408:00GlobeNewswire Inc.Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorNASDAQ:COGTCogent Biosciences Inc
26/02/202408:13Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:COGTCogent Biosciences Inc
26/02/202407:00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
22/02/202413:30GlobeNewswire Inc.Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisNASDAQ:COGTCogent Biosciences Inc
14/02/202415:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
14/02/202411:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:COGTCogent Biosciences Inc
14/02/202406:00GlobeNewswire Inc.Cogent Biosciences Announces Oversubscribed $225 Million Private PlacementNASDAQ:COGTCogent Biosciences Inc
05/02/202408:00GlobeNewswire Inc.Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingNASDAQ:COGTCogent Biosciences Inc
09/01/202407:00GlobeNewswire Inc.Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted TherapeuticsNASDAQ:COGTCogent Biosciences Inc
02/01/202407:00GlobeNewswire Inc.Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:COGTCogent Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:COGT

Su Consulta Reciente

NASDAQ
NVDA
NVIDIA
COIN
XRPUSD
Ripple
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
AMEX
SPY
SPDR S&P 500
COIN
AVAXUSD
Avalanche
FX
EURMXN
Euro vs MXN
NASDAQ
TSLA
Tesla
PM
XAUUSD
Gold vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
SPI
SP500
S&P 500
NYSE
KO
Coca Cola
AMEX
XLE
Energy Select Sector SPDR
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados